According to the World Health Organization (WHO) approved emergency Covaxin from Bharat Biotech, the medical journal Lancet has now determined that the vaccine, made in India, is 77.8 percent effective against symptomatic Covid, as the phase 3 data show. The efficacy data showed a protection of 70.8 percent against all variants of the SARS-CoV-2 virus.
The rate of effectiveness was confirmed by evaluating 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.
According to the Phase 3 data, Covaxin was found to be 65.2 percent effective against the Delta variant, 93.4 percent effective against severe symptomatic Covid, and 63.6 percent effective against asymptomatic Covid.
READ: WHO emergency approval for Covaxin, a Diwali gift to India: Covid Task Force Chief VK Paul
Dr. Krishna Ella, CMD of Bharat Biotech, said, “The peer review of data from Covaxin’s Phase III clinical trial in The Lancet, a leading voice in global medicine, confirms our commitment to data transparency and compliance with strict peer-to-peer review. Review standards of the world’s leading medical journals. This achievement reflects the unwavering commitment of my team members at Bharat Biotech, our public partners, the Indian Council of Medical Research, the National Institute of Virology, and the trust of our study participants in making this possible. “
The efficacy and safety study of the phase 3 study included 25,800 volunteers in 25 locations in India and is the largest clinical study in the country ever conducted for a Covid-19 vaccine.
Dr. Balram Bhargava, Director General of the Indian Council of Medical Research (ICMR), said, “I am pleased that the Phase III efficacy data has also been published in The Lancet, one of the most prestigious journals in the world, on Covaxin’s strong position among others global leaders in Covid-19 vaccines. “
“Covaxin’s journey from bank to bedside in less than 10 months shows the immense strength of Atmanirbhar Bharat working with Indian academia and industry in fighting adversity and carving out a niche in the global community,” he said.
On November 3, the World Health Organization issued emergency approval for the Covid-19 vaccine Covaxin from Bharat Biotech.
The WHO announcement came after the Technical Advisory Group (TAG), an independent advisory body to the world body, recommended Emergency Use List (EUL) status for Covaxin, and days after the TAG requested “additional clarifications” from Bharat Biotech in October 26 had to perform a final “risk-benefit assessment” of the vaccine for worldwide use.
إرسال تعليق